Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Calcifediol: Why, When, How Much?
Donati S, Marini F, Giusti F, Palmini G, Aurilia C, Falsetti I, Iantomasi T, Brandi ML. Donati S, et al. Among authors: aurilia c. Pharmaceuticals (Basel). 2023 Apr 22;16(5):637. doi: 10.3390/ph16050637. Pharmaceuticals (Basel). 2023. PMID: 37242420 Free PMC article. Review.
Autophagy-Related ncRNAs in Pancreatic Cancer.
Donati S, Aurilia C, Palmini G, Falsetti I, Iantomasi T, Brandi ML. Donati S, et al. Among authors: aurilia c. Pharmaceuticals (Basel). 2022 Dec 13;15(12):1547. doi: 10.3390/ph15121547. Pharmaceuticals (Basel). 2022. PMID: 36558998 Free PMC article. Review.
Parathyroid carcinoma: molecular therapeutic targets.
Marini F, Giusti F, Palmini G, Aurilia C, Donati S, Brandi ML. Marini F, et al. Among authors: aurilia c. Endocrine. 2023 Sep;81(3):409-418. doi: 10.1007/s12020-023-03376-w. Epub 2023 May 9. Endocrine. 2023. PMID: 37160841 Review.
Calcifediol: Mechanisms of Action.
Donati S, Palmini G, Aurilia C, Falsetti I, Marini F, Giusti F, Iantomasi T, Brandi ML. Donati S, et al. Among authors: aurilia c. Nutrients. 2023 Oct 17;15(20):4409. doi: 10.3390/nu15204409. Nutrients. 2023. PMID: 37892484 Free PMC article. Review.
Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia.
Falsetti I, Palmini G, Donati S, Aurilia C, Iantomasi T, Brandi ML. Falsetti I, et al. Among authors: aurilia c. Biomedicines. 2024 Apr 22;12(4):928. doi: 10.3390/biomedicines12040928. Biomedicines. 2024. PMID: 38672282 Free PMC article. Review.
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P; EUREkA study group. Caronna E, et al. Among authors: aurilia c. J Neurol Neurosurg Psychiatry. 2024 May 22:jnnp-2023-333295. doi: 10.1136/jnnp-2023-333295. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38777579
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; Italian Migraine Registry study group. Barbanti P, et al. Among authors: aurilia c. J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3. J Neurol. 2024. PMID: 38564057 Free PMC article. No abstract available.
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti P, Egeo G, Proietti S, d'Onofrio F, Aurilia C, Finocchi C, Di Clemente L, Zucco M, Doretti A, Messina S, Autunno M, Ranieri A, Carnevale A, Colombo B, Filippi M, Tasillo M, Rinalduzzi S, Querzani P, Sette G, Forino L, Zoroddu F, Robotti M, Valenza A, Camarda C, Borrello L, Aguggia M, Viticchi G, Tomino C, Fiorentini G, Orlando B, Bonassi S, Torelli P; Italian Migraine Registry study group. Barbanti P, et al. Among authors: aurilia c. Neurol Ther. 2024 Jun;13(3):611-624. doi: 10.1007/s40120-024-00591-z. Epub 2024 Mar 7. Neurol Ther. 2024. PMID: 38451463 Free PMC article.
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S; Italian Migraine Registry (I-GRAINE) study group. Barbanti P, et al. Among authors: aurilia c. J Neurol. 2024 May;271(5):2605-2614. doi: 10.1007/s00415-024-12192-9. Epub 2024 Feb 12. J Neurol. 2024. PMID: 38342785 Free PMC article.
119 results